Richard Daniell - Mar 3, 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Exec. VP, European Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
Stock symbol: TEVA
Transactions as of: Mar 3, 2024
Transactions value $: -$1,277,207
Form type: 4
Date filed: 3/5/2024, 04:21 PM
Previous filing: Mar 1, 2024
Next filing: Mar 7, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+62.3K	+89.22%		132K	Mar 3, 2024	Direct	F1, F2
transaction	TEVA	Ordinary Shares	Sale	-$830K	-62.3K	-47.15%	$13.34	69.8K	Mar 4, 2024	Direct	F1, F3, F4
transaction	TEVA	Ordinary Shares	Options Exercise		+33.5K	+48.03%		103K	Mar 4, 2024	Direct	F1, F2
transaction	TEVA	Ordinary Shares	Sale	-$447K	-33.5K	-32.45%	$13.34	69.8K	Mar 4, 2024	Direct	F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-62.3K	-25%	$0.00	187K	Mar 3, 2024	Ordinary Shares	62.3K	Direct	F1, F2, F5
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-33.5K	-33.33%	$0.00	67K	Mar 4, 2024	Ordinary Shares	33.5K	Direct	F1, F2, F6
transaction	TEVA	Restricted Share Units	Award	$0	+81.8K		$0.00	81.8K	Mar 4, 2024	Ordinary Shares	81.8K	Direct	F1, F2, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5	Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027.
F6	Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.
F7	Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.